Literature DB >> 3872313

Antimicrobial susceptibility and characterization of outer membrane proteins of Haemophilus ducreyi isolated in Thailand.

D N Taylor, P Echeverria, S Hanchalay, C Pitarangsi, L Slootmans, P Piot.   

Abstract

One hundred strains of Haemophilus ducreyi isolated in Thailand from patients with chancroid were tested by the agar dilution method against 10 antimicrobial agents and typed by outer membrane protein pattern by using sodium dodecyl sulfate gel electrophoresis. All strains produced beta-lactamase and were resistant to tetracycline, kanamycin, and sulfonamides. Most had a decreased susceptibility to trimethoprim (MIC for 50% of the strains [MIC50], 0.5 micrograms/ml) and chloramphenicol (MIC50, 8 micrograms/ml). Strains were susceptible to ciprofloxacin (MIC90, 0.001 micrograms/ml), ceftriaxone (MIC50, 0.0015 micrograms/ml), erythromycin (MIC50, 0.015 micrograms/ml), rosoxacin (MIC50, 0.03 micrograms/ml), and spectinomycin (MIC50, 8 micrograms/ml). The degree of antimicrobial resistance found in Thailand is higher than that reported for H. ducreyi isolated in other regions. Five different outer membrane protein patterns were found by analyzing proteins in the range of 29 to 61 kilodaltons, but 98% of the Thai strains fell into three patterns which did not differ greatly. Outer membrane protein patterns of Thai strains were also seen in strains from other geographic areas. A new outer membrane protein type was found among nine strains isolated in Singapore.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3872313      PMCID: PMC271681          DOI: 10.1128/jcm.21.3.442-444.1985

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  22 in total

1.  Antimicrobial susceptibility of Haemophilus ducreyi.

Authors:  G W Hammond; C J Lian; J C Wilt; A R Ronald
Journal:  Antimicrob Agents Chemother       Date:  1978-04       Impact factor: 5.191

2.  Single-dose thiamphenicol for chancroid.

Authors:  A S Latif; R Lencioni; P Crocchiolo; R Esposito
Journal:  Lancet       Date:  1982-11-27       Impact factor: 79.321

3.  Treatment of chancroid with erythromycin.

Authors:  J L Carpenter; A Back; D Gehle; T Oberhoffer
Journal:  Sex Transm Dis       Date:  1981 Jul-Sep       Impact factor: 2.830

4.  Isolation and identification of Haemophilus ducreyi in a clinical study.

Authors:  F O Sottnek; J W Biddle; S J Kraus; R E Weaver; J A Stewart
Journal:  J Clin Microbiol       Date:  1980-08       Impact factor: 5.948

5.  Molecular epidemiology of Haemophilus ducreyi infections.

Authors:  H H Handsfield; P A Totten; C L Fennel; S Falkow; K K Holmes
Journal:  Ann Intern Med       Date:  1981-09       Impact factor: 25.391

6.  Epidemiologic, clinical, laboratory, and therapeutic features of an urban outbreak of chancroid in North America.

Authors:  G W Hammond; M Slutchuk; J Scatliff; E Sherman; J C Wilt; A R Ronald
Journal:  Rev Infect Dis       Date:  1980 Nov-Dec

7.  Characteristics of Haemophilus ducreyi. A study.

Authors:  E H Sng; A L Lim; V S Rajan; A J Goh
Journal:  Br J Vener Dis       Date:  1982-08

8.  The role of Haemophilus ducreyi in penile ulcers in Bangkok, Thailand.

Authors:  D N Taylor; C Duangmani; C Suvongse; R O'Connor; C Pitarangsi; K Panikabutra; P Echeverria
Journal:  Sex Transm Dis       Date:  1984 Jul-Sep       Impact factor: 2.830

9.  Genital ulcers in Kenya. Clinical and laboratory study.

Authors:  H Nsanze; M V Fast; L J D'Costa; P Tukei; J Curran; A Ronald
Journal:  Br J Vener Dis       Date:  1981-12

10.  Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate.

Authors:  C H O'Callaghan; A Morris; S M Kirby; A H Shingler
Journal:  Antimicrob Agents Chemother       Date:  1972-04       Impact factor: 5.191

View more
  20 in total

Review 1.  Antimicrobial susceptibility of Haemophilus ducreyi.

Authors:  Y Dangor; R C Ballard; S D Miller; H J Koornhof
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

Review 2.  Treatment of chancroid.

Authors:  Y Dangor; R C Ballard; S D Miller; H J Koornhof
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

3.  Ribosomal DNA typing of Haemophilus ducreyi strains: proposal for a novel typing scheme.

Authors:  A Pillay; A A Hoosen; P Kiepiela; A W Sturm
Journal:  J Clin Microbiol       Date:  1996-10       Impact factor: 5.948

4.  Plasmid-mediated aminoglycoside phosphotransferases in Haemophilus ducreyi.

Authors:  M J Sanson-le Pors; I M Casin; E Collatz
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

5.  Molecular characterization of Haemophilus ducreyi by ribosomal DNA fingerprinting.

Authors:  S K Sarafian; T C Woods; J S Knapp; B Swaminathan; S A Morse
Journal:  J Clin Microbiol       Date:  1991-09       Impact factor: 5.948

6.  Antimicrobial susceptibilities of southern African isolates of Haemophilus ducreyi.

Authors:  Y Dangor; S D Miller; F da L Exposto; H J Koornhof
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

7.  In vitro activities of U-63366, a spectinomycin analog; roxithromycin (RU 28965), a new macrolide antibiotic; and five quinolone derivatives against Haemophilus ducreyi.

Authors:  M J Sanson-Le Pors; I M Casin; M C Thebault; G Arlet; Y Perol
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

8.  Efficacy and safety of a single dose therapy of a 500 mg ciprofloxacin tablet in chancroid patients.

Authors:  A Traisupa; C Wongba; P Tesavibul
Journal:  Infection       Date:  1988       Impact factor: 3.553

9.  Novel plasmid combinations in Haemophilus ducreyi isolates from Thailand.

Authors:  S K Sarafian; S R Johnson; M L Thomas; J S Knapp
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

10.  The major outer membrane protein of Haemophilus ducreyi is a member of the OmpA family of proteins.

Authors:  S M Spinola; G E Griffiths; K L Shanks; M S Blake
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.